However, immune checkpoint blockade (ICB)-based therapy using monoclonal antibodies (mAbs) against PD-1 and CTLA-4 failed to achieve clinical benefit in CLL [11,12]. This evidence concerns the gene CTLA4 and B-cell chronic lymphocytic leukemia.